Merck & Co., Inc. (LON:MRK)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 146.61B |
| Revenue (ttm) | 49.47B |
| Net Income (ttm) | 13.49B |
| Shares Out | n/a |
| EPS (ttm) | 5.32 |
| PE Ratio | 10.87 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,420 |
| Average Volume | 13,167 |
| Open | 58.80 |
| Previous Close | 58.50 |
| Day's Range | 58.25 - 58.80 |
| 52-Week Range | 48.00 - 77.00 |
| Beta | 0.69 |
| RSI | 53.23 |
| Earnings Date | Apr 24, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Mike Ashley’s Frasers buys £3m stake in Marks Electrical
In a stock market filing, Marks revealed that Frasers has bought 6.73 million shares in the business.
Three Quick Facts: AstraZeneca, Marks Electrical, BAE Systems
Buoyant demand sustains revenue growth at AstraZeneca, solid revenue growth at Marks Electrical, BAE Systems on track following upgrades